The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see forever…

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 12, 2014, Pages 2189-2193

  Bodei, Lisa ^a,b   Kidd, Mark ^b   Prasad, Vikas ^c   Baum, Richard P ^d   Drozdov, Ignat ^e   Modlin, Irvin M ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d ZENTRALKLINIK BAD BERKA   (Germany)

^e Bering Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOPHARMACEUTICAL AGENT;

COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC USE; HUMAN; NEUROENDOCRINE TUMOR; NUCLEAR MEDICINE; PROCEDURES; SCINTISCANNING; TRENDS;

HUMANS; NEUROENDOCRINE TUMORS; NUCLEAR MEDICINE; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 84938539612     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2836-1     Document Type: Editorial

References (44)

1. Modlin IM et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72.
2. Sundin A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26(6):803–18. doi:10.1016/j.bpg.2012.12.004.
3. Bodei L et al. Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Investig. 2009;32(4):360–9.
4. Gabriel M et al. 68Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48(4):508–18.
5. Koopmans KP et al. Improved staging of patients with carcinoid and islet cell tumors with 18 F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008;26(9):1489–95.
6. Orlefors H et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab. 2005;90(6):3392–400.
7. Baum RP, Kulkarni HR, Carreras C. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med. 2012;42(3):190–207. doi:10.1053/j.semnuclmed.2012.01.002.
8. Ambrosini V et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35(8):1431–8. Epub 2008 Apr 17.
9. Haug A et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36(5):765–70. Epub 2009 Jan 10.
10. Ambrosini V et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51(5):669–73. Epub 2010 Apr 15.
11. Campana D et al. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51(3):353–9. Epub 2010 Feb 11.
12. Binderup T et al. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16(3):978–85. Epub 2010 Jan 26.
13. Severi S et al. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(6):881–8. doi:10.1007/s00259-013-2369-z. Epub 2013 Feb 27.
14. Kwekkeboom DJ et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90(2):220–6.
15. Eisenhauer EA et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
16. Virgolini I et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004–10.
17. Poeppel TD et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52(12):1864–70. Epub 2011 Nov 9.
18. Kabasakal L et al. Comparison of (6)(8)Ga-DOTATATE and (6)(8)Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(8):1271–7. Epub 2012 Apr 20.
19. Sabet A et al. Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors. EJNMMI Res. 2013;3(1):82. doi:10.1186/2191-219X-3-82.
20. Kratochwil C et al. Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy. Q J Nucl Med Mol Imaging. 2014;2:2.
21. Garin E et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009;50(6):858–64. Epub 2009 May 14.
22. Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C, Göke B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51(9):1349–56. doi:10.2967/jnumed.110.075002.
23. Baum RP, Kulkarni HR. THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy—the Bad Berka experience. Theranostics. 2012;2(5):437–47. doi:10.7150/thno.3645. Epub 2012 May 7.
24. Pfeifer A et al. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med. 2012;53(8):1207–15. doi:10.2967/jnumed.111.101469. Epub 2012 Jul 10.
25. Mayerhoefer ME et al. Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen? Eur Radiol. 2012;22(4):938–46. Epub 2011 Nov 12.
26. Waser B et al. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009;50(6):936–41. doi:10.2967/jnumed.108.061457. Epub 2009 May 14.
27. Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012;53(9):1481–9.
28. Cescato R et al. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med. 2011;52(12):1886–90.
29. Wild D et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011;52(9):1412–7. doi:10.2967/jnumed.111.088922. Epub 2011 Aug 18.
30. Wild D et al. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med. 2008;359(7):766–8.
31. Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brändle M, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med. 2011;52(7):1073–8. doi:10.2967/jnumed.110.085142.
32. Selvaraju RK et al. In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4. J Nucl Med. 2013;54(8):1458–63. doi:10.2967/jnumed.112.114066. Epub 2013 Jun 12.
33. Eriksson O et al. Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. J Clin Endocrinol Metab. 2014;99(5):1519–24.
34. Waser B, Reubi JC. Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues. Eur J Nucl Med Mol Imaging. 2014;41(6):1166–71.
35. Fani M, Maecke HR. Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S11–30.
36. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30(5):781–93.
37. Sancho V, Di Florio A, Moody TW, Jensen RT. Bombesin receptor-mediated imaging and cytotoxicity: review and current status. Curr Drug Deliv. 2011;8(1):79–134.
38. Cescato R et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49(2):318–26.
39. Reubi JC. Old and new peptide receptor targets in cancer: future directions. Recent Results Cancer Res. 2013;194:567–76.
40. Ambrosini V et al. Radiopeptide imaging and therapy in Europe. J Nucl Med. 2011;52 Suppl 2:42S–55.
41. Nock BA et al. “To serve and protect”: enzyme inhibitors as radiopeptide escorts promote tumor targeting. J Nucl Med. 2014;55(1):121–7.
42. van Asselt SJ et al. Everolimus reduces 89Zr-Bevacizumab tumor uptake in patients with neuroendocrine tumors. J Nucl Med 2014.
43. Modlin IM et al. A nomogram to assess small-intestinal neuroendocrine tumor (‘carcinoid’) survival. Neuroendocrinology. 2010;92(3):143–57. Epub 2010 Aug 23.
44. Modlin I, Drozdov I, Kidd M. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. Plos One 2013. e63364.